Liu Jingzhen, chairman of China National Pharmaceutical Group Co Ltd (Sinopharm), held a meeting with Nikolai Snopkov, first deputy prime minister of Belarus, in Beijing on July 15. The discussions focused on their deep friendship established at the China-Belarus Great Stone Industrial Park, as well as their joint efforts in combating the COVID-19 pandemic and extensive cooperation in the healthcare sector.

Liu Jingzhen (front R), chairman of Sinopharm, talks with Nikolai Snopkov, first deputy prime minister of Belarus, in Beijing on July 15. [Photo/sinopharm.com]

Liu expressed a warm welcome to the first deputy prime minister, highlighting the comprehensive strategic partnership between China and Belarus. He reviewed the friendly cooperation between the two sides in medicine and health over the years, particularly the close collaboration in combating the COVID-19 pandemic. 

Liu reviewed Sinopharm’s recent achievements and its overall development strategy covering the entire lifecycle, industry chain and ecosystem. He emphasized the group’s commitment to strengthening cooperation with Belarus in the healthcare sector, enhancing the medical and health standards for the people of both nations, and contributing to the building of a global community of health for all. 

Snopkov thanked Sinopharm for supplying COVID-19 vaccines and supporting Belarus’ fight against the pandemic, noting that approximately 80 percent of Belarusians have received Chinese vaccines.

He appreciated the close cooperation between Sinopharm and Belarus in various healthcare fields and expressed his hope for deeper collaboration in such key areas as biomedicine, medical devices, pharmaceutical manufacturing and healthcare services.

Attending officials pose for a commemorative photo. [Photo/sinopharm.com] 

The meeting was attended by officials from the government of Belarus and the China-Belarus Great Stone Industrial Park, Sinopharm Deputy General Manager Jin Bin, China Ocean Aviation Group Limited Chairman Yu Xiaoyuan, and representatives from Sinopharm and its subsidiaries.